Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].
Hilbe W, Aigner K, Dittrich C, Eckmayr J, Fiegl M, Flicker M, Forstner B, Greil R, Jamnig H, Krajnik G, Lang A, Mohn-Staudner A, Schinko H, Studnicka M, Pirker R, Ploner F, Rothmund J, Schiller L, Zabernigg A, Zöchbauer-Müller S. Hilbe W, et al. Among authors: zabernigg a. Wien Klin Wochenschr. 2007;119(7-8):259-66. doi: 10.1007/s00508-007-0792-5. Wien Klin Wochenschr. 2007. PMID: 17492355 Review. German. No abstract available.
[Updated strategies in Small Cell Lung Cancer post ASCO 2007].
Hoschek S, Hoschek-Risslegger U, Fiegl M, Zabernigg A, Pall G, Auberger T, Gunsilius E, Schmid T, Jamnig H, Hilbe W. Hoschek S, et al. Among authors: zabernigg a. Wien Med Wochenschr. 2007;157(21-22):562-8. doi: 10.1007/s10354-007-0484-9. Wien Med Wochenschr. 2007. PMID: 18157594 Review. German.
[Small cell lung cancer].
Hoschek S, Hoschek-Risslegger U, Fiegl M, Zabernigg A, Pall G, Auberger T, Gunsilius E, Schmid T, Jamnig H, Hilbe W; Tiroler Arbeitskreis für Onkologie TAKO. Hoschek S, et al. Among authors: zabernigg a. Wien Klin Wochenschr. 2007;119(23-24):697-710. doi: 10.1007/s00508-007-0913-1. Wien Klin Wochenschr. 2007. PMID: 18157602 Review. German.
Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals.
Waldthaler C, Stauder R, Schnallinger M, Schreieck S, Hager J, Oexle H, Zangerl G, Verdorfer I, Zabernigg A, Gastl G, Fiegl M. Waldthaler C, et al. Among authors: zabernigg a. Wien Klin Wochenschr. 2011 May;123(9-10):269-75. doi: 10.1007/s00508-011-1558-7. Epub 2011 Apr 13. Wien Klin Wochenschr. 2011. PMID: 21479652
Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.
Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, Auberger J, Nevinny-Stickel M, Sterlacci W, Tzankov A, Jamnig H, Kohler K, Zabernigg A, Frötscher J, Oberaigner W, Fiegl M. Kocher F, et al. Among authors: zabernigg a. Lung Cancer. 2015 Feb;87(2):193-200. doi: 10.1016/j.lungcan.2014.12.006. Epub 2014 Dec 18. Lung Cancer. 2015. PMID: 25564398
Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study).
Hilbe W, Pall G, Kocher F, Pircher A, Zabernigg A, Schmid T, Schumacher M, Jamnig H, Fiegl M, Gächter A, Freund M, Kendler D, Manzl C, Zelger B, Popper H, Wöll E. Hilbe W, et al. Among authors: zabernigg a. PLoS One. 2015 May 28;10(5):e0125364. doi: 10.1371/journal.pone.0125364. eCollection 2015. PLoS One. 2015. PMID: 26020783 Free PMC article. Clinical Trial.
Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G, Greil R; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia. Fiegl M, et al. Among authors: zabernigg a. Cancer. 2006 Nov 15;107(10):2408-16. doi: 10.1002/cncr.22263. Cancer. 2006. PMID: 17054106 Free article.
67 results